



RNS Number : 9749C

Integrated Diagnostics Holdings PLC

05 September 2024

**NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.**

## **Integrated Diagnostics Holdings plc**

### **Completion of EGX Delisting**

**5 September 2024**

Integrated Diagnostics Holdings plc ("**IDH**" or the "**Company**") refers to:

- (i) the shareholder resolutions passed at the Company's Extraordinary General Meetings held on 12 June 2024 and 18 July 2024 approving, amongst other things, the voluntary delisting (the "**EGX Delisting**") of the Company's ordinary shares (the "**Shares**") from the Egyptian Exchange (the "**EGX**") and the Company's repurchase of the Shares from the beneficial owners of the Shares that were traded on the EGX and held by Misr for Central Depository and Registry ("**MCDR**") ("**EGX Shares**") if so required by such beneficial owners during the repurchase period;
- (ii) the Company's announcement on 13 August 2024 in relation to the timeline for the share buyback under the EGX's special operations market (OPR); and
- (iii) the Company's announcement on 27 August 2024 in relation to the share buyback under the EGX's special operations market (OPR).

Further to the Company's repurchase of 18,673,728 EGX Shares on 26 August 2024 pursuant to the share buyback under the EGX's special operations market (OPR), the EGX's Listing Committee has, on 4 September 2024, published a formal decision to delist the Shares from the EGX. As a result, the Company's listing information has been removed from the EGX's database, effective as at the commencement of the trading session on 5 September 2024.

Accordingly, the EGX Delisting has become effective and completed on 4 September 2024, and the last trading of the Shares on the EGX was 4 September 2024.

The Shares remain admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (the "**LSE**"), which is now the sole listing venue of the Company.

Following the completion of the EGX Delisting, all remaining EGX Shares that were not validly tendered into the special operations market (OPR) and repurchased by the Company pursuant to the share buyback are no longer eligible for trading on the EGX (such EGX Shares, the "**Remaining Shares**").

As set out in the Company's circular dated 1 July 2024, the Company will, in accordance with the Company's Articles of Association and the laws of Jersey, take such steps as are necessary to ensure that the Remaining Shares are not held by MCDR, and instead are held directly by the relevant underlying beneficial owners (the "**Remaining Shareholders**") as set out in the register maintained by MCDR as at the date of completion of the EGX Delisting. Such steps include, amongst other things, making the relevant entries in the Company's register of members to reflect the Remaining Shareholders as the holders of their respective Remaining Shares in place of MCDR, and issuing and despatching share certificates to the Remaining Shareholders in respect of their respective holdings of Remaining Shares.

Thereafter, a Remaining Shareholder can, should they so wish, elect at their own cost to engage a broker with the necessary facilities to dematerialise and hold their Remaining Shares in a form that allows such Shares to be traded on the main market for listed securities of the LSE via CREST (subject to all required steps having been taken, including obtaining the consent by and engagement of such broker, and subject to all applicable rules and procedures of CREST and the LSE).

Remaining Shareholders are required to come to their own decisions in respect of their Remaining Shares and, in the event of any doubt about the contents of this announcement or what action should be taken, they are recommended to seek their own personal financial, legal or tax advice from a stockbroker, legal, tax or other appropriately authorised independent financial adviser on the possible and recommended actions to be taken in respect of their Remaining Shares. The Company notes that the Company cannot provide, and is not purporting to provide, any financial, legal or tax advice in relation to any possible actions that could be taken in respect of the Remaining Shares.

For further information please contact:

**Integrated Diagnostics Holdings plc**

**Tarek Yehia**

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | [tarek.yehia@idhcorp.com](mailto:tarek.yehia@idhcorp.com)

**Company Secretary**

## Company Matters

[IDHLondon@linkgroup.co.uk](mailto:IDHLondon@linkgroup.co.uk)

-Ends-

### About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar in Sudan (both in Sudan), and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditation. The Group's portfolio of over 3,000 diagnostics tests. From its base of 601 branches as of 31 December 2023, IDH served over 100 million patients and performed more than 36.1 million tests in 2023. IDH will continue to add laboratories through its Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH is a Jersey-registered entity whose Shares are admitted to the equity (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange since May 2015 (IDHC).

Learn more at [idhcorp.com](http://idhcorp.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCKZGGLMDNGDZZ